• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management.非酒精性脂肪性肝病在瘦人群体中的:预后、结局和管理。
World J Gastroenterol. 2020 Nov 14;26(42):6514-6528. doi: 10.3748/wjg.v26.i42.6514.
2
Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.瘦型非酒精性脂肪性肝病患者的肝脏和心血管损伤,及其与内脏肥胖的关系。
Clin Gastroenterol Hepatol. 2017 Oct;15(10):1604-1611.e1. doi: 10.1016/j.cgh.2017.04.045. Epub 2017 May 26.
3
Association between the lean nonalcoholic fatty liver disease and risk of incident type 2 diabetes in a healthy population of Northwest China: a retrospective cohort study with a 2-year follow-up period.瘦型非酒精性脂肪性肝病与中国西北地区健康人群 2 型糖尿病发病风险的关联:一项 2 年随访期的回顾性队列研究。
Front Endocrinol (Lausanne). 2023 Jun 26;14:1173757. doi: 10.3389/fendo.2023.1173757. eCollection 2023.
4
Clinical Characteristics and Metabolic Profiles of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Patients and Their Comparison with Obese and Overweight NAFLD.瘦型非酒精性脂肪性肝病(NAFLD)患者的临床特征和代谢特征及其与肥胖和超重 NAFLD 的比较。
J Assoc Physicians India. 2022 Apr;70(4):11-12.
5
AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.AGA 临床实践更新:瘦个体中非酒精性脂肪性肝病的诊断和管理:专家评论。
Gastroenterology. 2022 Sep;163(3):764-774.e1. doi: 10.1053/j.gastro.2022.06.023. Epub 2022 Jul 14.
6
Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease.非酒精性脂肪性肝病瘦型中国成年人的患病率、临床特征、危险因素和指标。
World J Gastroenterol. 2020 Apr 21;26(15):1792-1804. doi: 10.3748/wjg.v26.i15.1792.
7
Different predictors of steatosis and fibrosis severity among lean, overweight and obese patients with nonalcoholic fatty liver disease.非酒精性脂肪性肝病的瘦、超重和肥胖患者中,肝脂肪变性和纤维化严重程度的不同预测因素。
Dig Liver Dis. 2019 Oct;51(10):1392-1399. doi: 10.1016/j.dld.2019.02.019. Epub 2019 Mar 28.
8
The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.台湾地区体重指数对非酒精性脂肪性肝病临床病理特征的影响。
J Gastroenterol Hepatol. 2022 Oct;37(10):1901-1910. doi: 10.1111/jgh.15936. Epub 2022 Jul 13.
9
Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease.系统评价与荟萃分析:非酒精性脂肪性肝病瘦型患者组织学疾病严重程度的意义。
Aliment Pharmacol Ther. 2018 Jan;47(1):16-25. doi: 10.1111/apt.14401. Epub 2017 Oct 30.
10
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.全球非肥胖或消瘦非酒精性脂肪性肝病的患病率、发病率和结局:系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2020 Aug;5(8):739-752. doi: 10.1016/S2468-1253(20)30077-7. Epub 2020 May 12.

引用本文的文献

1
Outcomes of Acute Pancreatitis in Lean Versus Non-lean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Patients: A Nationwide Analysis.瘦型与非瘦型代谢功能障碍相关脂肪性肝病(MASLD)患者急性胰腺炎的结局:一项全国性分析
Dig Dis Sci. 2025 Jul 26. doi: 10.1007/s10620-025-09245-y.
2
Clinical Outcomes in Acute Decompensated Metabolic Dysfunction-associated Steatotic Liver Disease Cirrhosis: The Role of BMI in Mortality, Readmission, and Hospital Stay.急性失代偿性代谢功能障碍相关脂肪性肝病肝硬化的临床结局:体重指数在死亡率、再入院率和住院时间方面的作用
J Gen Intern Med. 2025 Jul 7. doi: 10.1007/s11606-025-09710-4.
3
Comparative application of MAFLD and MASLD diagnostic criteria on NAFLD patients: insights from a single-center cohort.MAFLD和MASLD诊断标准在非酒精性脂肪性肝病患者中的比较应用:来自单中心队列的见解
Clin Exp Med. 2025 Jan 14;25(1):36. doi: 10.1007/s10238-024-01553-3.
4
Endonuclease G promotes hepatic mitochondrial respiration by selectively increasing mitochondrial tRNA production.核酸内切酶G通过选择性增加线粒体tRNA的产生来促进肝脏线粒体呼吸。
Proc Natl Acad Sci U S A. 2025 Jan 7;122(1):e2411298122. doi: 10.1073/pnas.2411298122. Epub 2025 Jan 3.
5
Diagnosis and Management of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review.瘦素代谢功能障碍相关脂肪性肝病(MASLD)的诊断与管理:一项系统评价
Cureus. 2024 Oct 14;16(10):e71451. doi: 10.7759/cureus.71451. eCollection 2024 Oct.
6
Clinical characteristics of lean metabolic-associated fatty liver disease and the impact of concurrent diabetes mellitus.瘦素介导的代谢相关脂肪性肝病的临床特征及合并糖尿病的影响
Tzu Chi Med J. 2024 Jul 3;36(4):425-432. doi: 10.4103/tcmj.tcmj_253_23. eCollection 2024 Oct-Dec.
7
Diagnostic Utility of Triglyceride-Glucose Index in Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study on Lean Population.甘油三酯-葡萄糖指数在非酒精性脂肪性肝病中的诊断效用:一项针对瘦人群体的横断面研究
Diabetes Metab Syndr Obes. 2024 Sep 21;17:3547-3556. doi: 10.2147/DMSO.S469398. eCollection 2024.
8
Metabolic dysfunction associated fatty liver disease in healthy weight individuals.代谢功能障碍相关的健康体重个体的脂肪肝疾病。
Hepatol Int. 2024 Oct;18(Suppl 2):884-896. doi: 10.1007/s12072-024-10662-w. Epub 2024 Jul 25.
9
Association between metabolic dysfunction-associated steatotic liver disease and myosteatosis measured by computed tomography.通过计算机断层扫描测量的代谢功能障碍相关脂肪性肝病与肌脂肪变性之间的关联。
J Cachexia Sarcopenia Muscle. 2024 Oct;15(5):1942-1952. doi: 10.1002/jcsm.13543. Epub 2024 Jul 16.
10
Exploring Fibrosis Pathophysiology in Lean and Obese Metabolic-Associated Fatty Liver Disease: An In-Depth Comparison.探讨瘦型和肥胖型代谢相关脂肪性肝病中纤维化发病机制的异同。
Int J Mol Sci. 2024 Jul 5;25(13):7405. doi: 10.3390/ijms25137405.

本文引用的文献

1
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.全球非肥胖或消瘦非酒精性脂肪性肝病的患病率、发病率和结局:系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2020 Aug;5(8):739-752. doi: 10.1016/S2468-1253(20)30077-7. Epub 2020 May 12.
2
Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease.非酒精性脂肪性肝病瘦型中国成年人的患病率、临床特征、危险因素和指标。
World J Gastroenterol. 2020 Apr 21;26(15):1792-1804. doi: 10.3748/wjg.v26.i15.1792.
3
Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016.1999-2016 年美国肥胖、非肥胖和瘦型非酒精性脂肪性肝病(NAFLD)的流行率、特征和死亡率结局。
J Intern Med. 2020 Jul;288(1):139-151. doi: 10.1111/joim.13069. Epub 2020 Apr 22.
4
Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease.羟基类固醇17-β脱氢酶13变体增加磷脂并预防非酒精性脂肪性肝病中的纤维化。
JCI Insight. 2020 Mar 12;5(5):132158. doi: 10.1172/jci.insight.132158.
5
Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients.强化饮食和生活方式干预在瘦型非酒精性脂肪性肝病患者治疗中的作用。
Eur J Gastroenterol Hepatol. 2020 Oct;32(10):1352-1357. doi: 10.1097/MEG.0000000000001656.
6
Non-alcoholic fatty liver disease in lean individuals.瘦人非酒精性脂肪性肝病
JHEP Rep. 2019 Aug 30;1(4):329-341. doi: 10.1016/j.jhepr.2019.08.002. eCollection 2019 Oct.
7
Early Predictors of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease: Non-obese Versus Obese Patients.非酒精性脂肪性肝病患者心血管疾病风险的早期预测因素:非肥胖与肥胖患者。
Dig Dis Sci. 2020 Jun;65(6):1850-1860. doi: 10.1007/s10620-019-05926-7. Epub 2019 Nov 13.
8
Comparison of clinical characteristics between lean and obese nonalcoholic fatty liver disease in the northeast Chinese population.中国东北人群中瘦型与肥胖型非酒精性脂肪性肝病临床特征的比较
Arch Med Sci Atheroscler Dis. 2019 Aug 6;4:e191-e195. doi: 10.5114/amsad.2019.87122. eCollection 2019.
9
Relationship Between Serum Uric Acid Levels and Nonalcoholic Fatty Liver Disease in Non-Obese Patients.血清尿酸水平与非肥胖患者非酒精性脂肪肝的关系。
Medicina (Kaunas). 2019 Sep 17;55(9):600. doi: 10.3390/medicina55090600.
10
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation.瘦型非酒精性脂肪性肝病:一种由不同代谢适应塑造的独特实体。
Hepatology. 2020 Apr;71(4):1213-1227. doi: 10.1002/hep.30908. Epub 2020 Jan 24.

非酒精性脂肪性肝病在瘦人群体中的:预后、结局和管理。

Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management.

机构信息

First Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens 11527, Greece.

First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki 54636, Greece.

出版信息

World J Gastroenterol. 2020 Nov 14;26(42):6514-6528. doi: 10.3748/wjg.v26.i42.6514.

DOI:10.3748/wjg.v26.i42.6514
PMID:33268944
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7673972/
Abstract

Nonalcoholic fatty liver disease (NAFLD) accounts for most cases of chronic liver disease worldwide, with an estimated global prevalence of approximately 25% and ranges from simple steatosis to nonalcoholic steatohepatitis and cirrhosis. NAFLD is strongly connected to metabolic syndrome, and for many years, fatty liver was considered to be an exclusive feature of obese patients. However, recent studies have highlighted the presence of NAFLD in non-obese subjects, with or without increased visceral fat or even in lean subjects without increased waist circumference. "Lean NAFLD" is a relatively new concept and there is significant scientific interest in understanding the differences in pathophysiology, prognosis and management compared with NAFLD in overweight/obese patients. In the present editorial, we discuss the clinical and metabolic profiles and outcomes of lean NAFLD compared with both obese NAFLD and lean healthy individuals from Asian and Western countries. Moreover, we shed light to the challenging topic of management of NAFLD in lean subjects since there are no specific guidelines for this population. Finally, we discuss open questions and issues to be addressed in the future in order to categorize NAFLD patients into lean and non-lean cohorts.

摘要

非酒精性脂肪性肝病(NAFLD)占全球慢性肝病的大多数,其全球患病率约为 25%,范围从单纯性脂肪变性到非酒精性脂肪性肝炎和肝硬化。NAFLD 与代谢综合征密切相关,多年来,脂肪肝被认为是肥胖患者特有的特征。然而,最近的研究强调了非肥胖人群中存在 NAFLD,无论是否存在内脏脂肪增加,甚至在没有腰围增加的瘦人群体中也是如此。“瘦型 NAFLD”是一个相对较新的概念,科学界对其与超重/肥胖患者的 NAFLD 在病理生理学、预后和管理方面的差异非常感兴趣。在本期社论中,我们讨论了来自亚洲和西方国家的瘦型 NAFLD 与肥胖型 NAFLD 和瘦型健康个体的临床和代谢特征以及结局。此外,我们还探讨了瘦型人群中 NAFLD 管理这一具有挑战性的话题,因为针对这一人群尚无特定的指南。最后,我们讨论了一些悬而未决的问题和需要在未来解决的问题,以便将 NAFLD 患者分为瘦型和非瘦型队列。